HLTRF News and Press, HLS Therapeutics Inc From 09/30/20

HLS Therapeutics Acquires Portfolio of Four Royalty Interests Canada NewsWire TORONTO, Sept. 30, 2020 HLS anticipates the portfolio will generate sustained and diversified revenues and cash flows Portfolio forecasted to generate an IRR in excess of 20% pe...

HLS Therapeutics Comments on U.S. Court of Appeals Decision in Amarin Patent Litigation Canada NewsWire TORONTO, Sept. 3, 2020 U.S. decision does not relate to Vascepa in Canada Vascepa was granted 8 years of data exclusivity by Health Canada upon approval Vascep...

VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020 Canada NewsWire TORONTO, Aug. 31, 2020 Primary endpoint of slowed coronary plaque progression reported to have been met with VAS...

HLS Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference Canada NewsWire TORONTO, Aug. 7, 2020 TORONTO , Aug. 7, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous...

HLS Therapeutics ( OTCPK:HLTRF ) : Q2 GAAP EPS of -$0.20. More news on: HLS Therapeutics Inc., Earnings news and commentary, Tech stocks news, Read more ...

HLS Therapeutics Announces Q2 2020 Financial Results Canada NewsWire TORONTO, Aug. 6, 2020 Revenue of $12.6 million and Adjusted EBITDA of $4.8 million Increasing peak-year sales estimate for Vascepa to C$275 -325 million Clozaril's Canadian patient count and ...

HLS Therapeutics to Host Q2 2020 Financial Results Conference Call Canada NewsWire TORONTO, July 30, 2020 TORONTO , July 30, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 2020 financial results by press relea...

HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa® (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price Canada NewsWire TORONTO, July 20, 2020 CADTH recommends Vascepa be rei...

HLS Therapeutics to Present at the Raymond James Human Health Innovation Conference Canada NewsWire TORONTO, June 17, 2020 TORONTO , June 17, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central ...

HLS Therapeutics Confirms Annual Shareholders' Meeting Canada NewsWire TORONTO, ON, June 10, 2020 TORONTO, ON , June 10, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and ...